{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:33:58Z","timestamp":1792787638100,"version":"4.5.0"},"reference-count":52,"publisher":"American Society for Clinical Investigation","issue":"8","funder":[{"name":"National Cancer Center","award":["R21 CA197878"],"award-info":[{"award-number":["R21 CA197878"]}]},{"name":"National Cancer Center","award":["R01 CA200551"],"award-info":[{"award-number":["R01 CA200551"]}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"crossref","award":["R01 AI095239"],"award-info":[{"award-number":["R01 AI095239"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4,19]]},"abstract":"<jats:p>\n                    Although immune checkpoint inhibitors have resulted in durable clinical benefits in a subset of patients with advanced cancer, some patients who did not respond to initial anti\u2013PD-1 therapy have been found to benefit from the addition of salvage chemotherapy. However, the mechanism responsible for the successful chemoimmunotherapy is not completely understood. Here we show that a subset of circulating CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells expressing the chemokine receptor CX3CR1 are able to withstand the toxicity of chemotherapy and are increased in patients with metastatic melanoma who responded to chemoimmunotherapy (paclitaxel and carboplatin plus PD-1 blockade). These CX3CR1\n                    <jats:sup>+<\/jats:sup>\n                    CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells have effector memory phenotypes and the ability to efflux chemotherapy drugs via the ABCB1 transporter. In line with clinical observation, our preclinical models identified an optimal sequencing of chemoimmunotherapy that resulted in an increase of CX3CR1\n                    <jats:sup>+<\/jats:sup>\n                    CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells. Taken together, we found a subset of PD-1 therapy\u2013responsive CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells that were capable of withstanding chemotherapy and executing tumor rejection with their unique abilities of drug efflux (ABCB1), cytolytic activity (granzyme B and perforin), and migration to and retention (CX3CR1 and CD11a) at tumor sites. Future strategies to monitor and increase the frequency of CX3CR1\n                    <jats:sup>+<\/jats:sup>\n                    CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells may help to design effective chemoimmunotherapy to overcome cancer resistance to immune checkpoint blockade therapy.\n                  <\/jats:p>","DOI":"10.1172\/jci.insight.97828","type":"journal-article","created":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T11:02:49Z","timestamp":1524049369000},"source":"Crossref","is-referenced-by-count":167,"title":["CX3CR1 identifies PD-1 therapy\u2013responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy"],"prefix":"10.1172","volume":"3","author":[{"given":"Yiyi","family":"Yan","sequence":"first","affiliation":[{"name":"Division of Medical Oncology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Urology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Harrington","sequence":"additional","affiliation":[{"name":"Department of Urology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy E.","family":"Bindeman","sequence":"additional","affiliation":[{"name":"Department of Urology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex A.","family":"Adjei","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology,"},{"name":"Mayo Clinic Cancer Center Early Therapeutic Program,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Sung","family":"Jang","sequence":"additional","affiliation":[{"name":"Mayo Clinic Center of Individualized Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Jen","sequence":"additional","affiliation":[{"name":"Mayo Clinic Center of Individualized Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Biomedical Statistics and Informatics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pritha","family":"Chanana","sequence":"additional","affiliation":[{"name":"Department of Biomedical Statistics and Informatics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Mansfield","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean S.","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetomir N.","family":"Markovic","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana S.","family":"Dronca","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5782-2983","authenticated-orcid":true,"given":"Haidong","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Urology,"},{"name":"Department of Immunology, Mayo Clinic, Rochester, Minnesota, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"232","published-online":{"date-parts":[[2018,4,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2016.0051"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.9861"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30498-3"},{"issue":"(15_suppl);","key":"B4","article-title":"The Mayo Clinic experience in patients with metastatic melanoma who have failed previous pembrolizumab treatment","volume":"34","author":"Yan","year":"2016","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.1529"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.10.011"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.12543"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nri2216"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noq157"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2007.10.004"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1172\/JCI15175"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-006-0225-8"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25035"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nri2970"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0301"},{"key":"B16","article-title":"Combinatorial strategies for the induction of immunogenic cell death","volume":"6","author":"Bezu","year":"2015","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1172\/JCI73639"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4161\/onci.23972"},{"issue":"6","key":"B20","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.86014","article-title":"T cell Bim levels reflect responses to anti-PD-1 cancer therapy","volume":"1","author":"Dronca","year":"2016","journal-title":"JCI Insight"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.4059"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1084\/jem.172.6.1735"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01776-13"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20020666"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nature22079"},{"key":"B28","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms9306","article-title":"Functional classification of memory CD8(+) T cells by CX3CR1 expression","volume":"6","author":"B\u00f6ttcher","year":"2015","journal-title":"Nat Commun"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.09.015"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nrc706"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(02)00169-2"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3825"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003976"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2012.30"},{"key":"B35","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2011.137","article-title":"ERK2 phosphorylation of serine 77 regulates Bmf pro-apoptotic activity","volume":"3","author":"Shao","year":"2012","journal-title":"Cell Death Dis"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-9822(01)00199-3"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M603912200"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80438-9"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.10.018"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.12.6173"},{"key":"B41","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-016-0125-1","article-title":"Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine\/CX3CL1 expressing tumors: importance of the chemokine gradient","volume":"4","author":"Siddiqui","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22660"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10816"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/jso.23095"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-008-9876-3"},{"issue":"21","key":"B46","first-page":"7468","article-title":"Fractalkine mediates natural killer-dependent antitumor responses in vivo","volume":"63","author":"Lavergne","year":"2003","journal-title":"Cancer Res"},{"key":"B47","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12624","article-title":"Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma","volume":"7","author":"Wallin","year":"2016","journal-title":"Nat Commun"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvp341"},{"issue":"1","key":"B49","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1124\/jpet.105.093039","article-title":"Proline 326 in the C terminus of murine CX3CR1 prevents G-protein and phosphatidylinositol 3-kinase-dependent stimulation of Akt and extracellular signal-regulated kinase in Chinese hamster ovary cells","volume":"316","author":"Davis","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-3041"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200526042"},{"key":"B52","article-title":"B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8+T cells","volume":"6","author":"Liu","year":"2016","journal-title":"Sci Rep"}],"container-title":["JCI Insight"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/insight.jci.org\/articles\/view\/97828\/files\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:01:10Z","timestamp":1779195670000},"score":1,"resource":{"primary":{"URL":"https:\/\/insight.jci.org\/articles\/view\/97828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,19]]},"references-count":52,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,4,19]]},"published-print":{"date-parts":[[2018,4,19]]}},"alternative-id":["10.1172\/jci.insight.97828"],"URL":"https:\/\/doi.org\/10.1172\/jci.insight.97828","relation":{},"ISSN":["2379-3708"],"issn-type":[{"value":"2379-3708","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,19]]},"article-number":"e97828"}}